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Abstract
Background: Duchenne and Becker muscular dystrophy (DMD and BMD) are X-chromosomal recessive neuromuscular
disorders that are caused by mutations in the dystrophin gene and characterized by cardiac involvement. Circulating
microRNAs (miRNAs) have been proposed as diagnostic biomarkers for various cardiovascular diseases. However,
circulating miRNAs reflecting the presence and/or disease severity of cardiac involvement in DMD/BMD patients have
not been described so far.
Methods: Sixty-three male patients with known MD and 26 age-matched healthy male controls were prospectively
enrolled. All MD patients and controls underwent comprehensive cardiovascular magnetic resonance (CMR) studies
as well as venous blood sampling on the same day.
Results: An impaired left ventricular (LV) systolic function (defined as LV-EF <55 %) was detected in 29 (46 %) and
presence of late gadolinium enhancement (LGE) indicative of myocardial fibrosis in 48 (76 %) MD patients with an
exclusively non-ischemic pattern. Whereas no significant differences were observed for the 27 selected circulating
miRNAs in MD patients with abnormal CMR findings (comprising structural and/or functional impairments) compared
to those with completely normal CMR studies, a significant up-regulation of three miRNAs was observed in LGE-
positive MD patients compared to LGE-negative ones: miR-222 (1.8-fold, p = 0.035), miR-26a (2.1-fold, p = 0.03) and
miR-378a-5p (2.4-fold, p = 0.026). A signature of these three miRNAs (miR-26a, miR-222 and miR-378a-5p)
resulted in an area under the curve (AUC) value of 0.74 for the diagnosis of LGE-positive MD patients. In a
multivariable model, three independent predictors for LGE presence were identified comprising not only
clinical and laboratory markers (LV-EF: OR 0.47, 95 % CI 0.24-0.89, p = 0.021 and elevated hs-Trop: OR 2559, 95 % CI
2.97-22.04*105, p = 0.023) but also the circulating miR-222 (OR 938, 95 % CI 938.46, 3.56-24.73*104, p = 0.016).
Conclusions: Up-regulation of circulating miRNAs miR-222, miR-26a and miR-378a-5p indicates the presence
of myocardial scars in MD patients. Plasma miR-222 appears to be a promising novel biomarker reflecting
structural – but not functional – cardiac alterations in MD patients.
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Background
Duchenne and Becker muscular dystrophy (DMD and
BMD) are X-chromosomal recessive neuromuscular disor-
ders that are caused by mutations in the dystrophin gene
that subsequently lead to either total absence or structural
impairment of the dystrophin protein. Since dystrophin is
a central protein in the cell membrane of skeletal as well
as cardiac muscle cells, MD patients do not only suffer
from skeletal muscle weakness and wasting but also from
progressive cardiomyopathy [1, 2]. Since therapeutic treat-
ment options for respiratory failure have tremendously
improved within the last years, cardiac disease with a
characteristic, non-ischemic pattern of left ventricular
(LV) myocardial fibrosis leading to non-ischemic dilated
cardiomyopathy, heart failure symptoms and ventricular
arrhythmias has become a major cause of morbidity and
mortality in MD patients [1, 3–5].
Within the last years, cardiovascular magnetic reson-
ance (CMR) has evolved as an excellent tool for the early
and sensitive diagnosis of cardiac involvement in MD pa-
tients, since this imaging modality does not only allow an
accurate functional assessment of the human heart - but
also enables non-invasive myocardial fibrosis detection
based on techniques such as late gadolinium enhancement
(LGE)-imaging or T1-mapping [6–8]. However, previous
CMR-based studies in MD patients have also suggested
that cardiac serum markers such as troponin or brain-
natriuretic peptide (BNP) that are helpful to diagnose and
monitor cardiac disease in many ischemic as well as non-
ischemic cardiomyopathies, are of limited clinical value in
MD patients [9, 10]. Hence, the identification of novel
serum biomarkers for diagnosis and monitoring of cardio-
myopathy in MD patients (e.g. as a gatekeeper for subse-
quent CMR studies) is a clinically important, however, still
unsolved challenge.
Recent advances in molecular diagnostics have opened
novel avenues in defining the molecular basis and under-
lying pathophysiology of inherited diseases. In particular,
microRNAs (miRNAs) have been identified as a novel
class of both biomarkers and targets for therapy [11]. miR-
NAs are small (19–25 nucleotides), non-coding molecules
and can modify gene expression by regulating mRNA sta-
bility or translation and thereby modify essential cellular
functions [12]. Recent studies have shown that miRNAs
are not only located inside cells (where they exert their
function) but can also be found in different fluids such as
blood [13]. Moreover, there is a growing body of evidence
that circulating miRNAs can be used as diagnostic as well
as prognostic biomarkers for different cardiovascular dis-
eases [14, 15]. However, circulating miRNAs reflecting the
presence and/or disease severity of cardiac involvement in
DMD/BMD patients have not been described so far.
Hence, the aim of the current study was to identify
specific circulating miRNAs in the plasma of DMD/BMD
patients that would allow a non-invasive and accurate
diagnosis of cardiac disease in these patients.
Methods
Study population
As part of an ongoing prospective study, 63 male patients
with known MD were prospectively enrolled between
2008 and 2015. A diagnosis of DMD (N = 12) or BMD
(N = 51) has previously been made in specialized neur-
ology centers based on clinical data, skeletal muscle
pathology with dystrophin analyses and/or genetic test-
ing [10, 16–18]. The clinical degree of skeletal myop-
athy was clinically assessed as follows: 0 = no clinical
signs of myopathy; 1 = able to walk, unable to run; 2 =
unable to walk; 3 = unable to use hands.
In addition, 26 age-matched healthy male controls
were enrolled between 2011 and 2014 and represented
the control group. All MD patients and controls under-
went comprehensive CMR studies as well as venous
blood sampling on the same day. The study protocol
complies with the Declaration of Helsinki and was ap-
proved by the local ethics committee (Ethik-Kommission
Landesärztekammer Baden-Württemberg, Stuttgart, Germany).
Informed consent was obtained from the patients prior to
study inclusion.
Blood sampling in MD patients and controls
EDTA blood samples were collected on the same day of
the CMR study. EDTA plasma was harvested by centr-
ifugation of EDTA Blood Collection Tubes (Sarstedt,
Germany) for 10 min at 4000 rpm. Aliquots of plasma
supernatant were stored in cryotubes (Sarstedt, Germany)
at −20 °C until use. Both in MD patients and controls,
laboratory determinations for cardiac biomarkers - high
sensitive troponin I (hs-Trop) and brain natriuretic-
peptide (NT-proBNP) - were performed using standard
methods and considered elevated when serum levels
exceeded the upper laboratory reference limit. In addition,
creatine kinase (CK) levels were determined.
miRNA extraction and quantification
RNA was extracted from 400 μl of plasma using mirVana
miRNA isolation kit (Life technologies, USA) following
the manufacturer’s protocol, eluted in 75 μl elution
solution and stored at −80 °C.
miRNA selection for quantification was based on litera-
ture data related to either cardiovascular diseases and/or
DMD/BMD (Additional file 1: Table S1) were reverse
transcribed using TaqMan MicroRNA Reverse Transcrip-
tion Kit (Life technologies, USA). Individual stem-loop re-
verse transcription primers included in the predeveloped
TaqMan miRNA assay (Life technologies, USA) were
pooled at a final dilution of 0.05x for each primer. The
final RT reaction volume of 7.5 μl contained 0.15 μl
Becker et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:25 Page 2 of 14
100 mM dNTP, 1.5 μl multiscribe reverse transcriptase
(50 U/μl), 0.75 μl 10 × RT buffer, 0.095 μl RNase
inhibitor (20 U/μl), 3 μl primer pool and 2 μl of total
RNA. The reaction was performed following condi-
tions of manufacturer.
To improve sensitivity of miRNA quantification, a pre-
amplification reaction was performed. TaqMan miRNA
assays included in the TaqMan miRNA assay (Life tech-
nologies, USA) were pooled at a final dilution of 0.2x for
each assay. Pre-amplification reaction was done at 10 μl
final volume containing 5 μl TaqMan PreAmp Master
Mix (2X), 1.5 μl of assay pool, 2.5 μl of nuclease-free
water and 1 μl of cDNA. The pre-amplification PCR was
run according to the manufacturer’s protocol, the pre-
amplification PCR product was diluted 1:5 with suspen-
sion buffer (Teknova AS, Norway) and stored at −20 °C
until need.
The miRNA expression levels were quantified by real-
time PCR using TaqMan® Universal Master Mix II (no
UNG) and TaqMan miRNA assays (Life technologies,
USA) on a real-time PCR BioMark system (Fluidigm
Corporation, USA) following the manufacturer’s protocol.
Relative levels of miRNA expression were calculated by
normalization to expression levels of miR-16 and there-
after multiplied by 103 in order to increase readability in
the respective tables. The following miRNAs had to be ex-
cluded from final analysis due to failing measurements:
miR-1, miR-31, miR-34c, miR-95, miR-133a, miR-208a,
miR-208b, miR-499a-3p, miR-499a-5p and miR-539.
CMR data acquisition
ECG-gated CMR studies were performed on a 1.5-T scan-
ner (Aera, Siemens Medical Solutions, Erlangen, Germany)
using commercially available cardiac software, electrocar-
diographic triggering, and cardiac-dedicated surface coils.
Cine-imaging was performed using a steady-state-free-pre-
cession (SSFP) sequence in three long-axis slices (four-,
three- and two-chamber) and a stack of short-axis slices
completely covering the LV. LGE-imaging was performed
using a T1-weighted inversion recovery gradient-echo se-
quence 10–15 min after intravenous contrast administra-
tion (0.15 mmol/kg Magnevist®) in the same imaging
planes as the cine-images.
CMR data analysis
CMR analysis was performed off-line by two experienced
readers blinded to gender and clinical characteristics.
Ventricular volumes, ejection fraction and LV mass were
derived by contouring endo- and epicardial borders on the
short-axis cine images and indexed to body surface area.
LGE presence and pattern were first visually assessed on
the short-and long-axis images by using the 16-segment
AHA model [16]. Second, LGE extent was planimetered
on the short-axis contrast images with the use of ImageJ
software (National Institutes of Health, Bethesda, Md,
USA) and an image intensity level ≥3 SD above the mean
of remote myocardium was used to define LGE indicative
of damaged myocardium as described previously (National
Institutes of Health, Bethesda, Md, USA) and expressed as
percentage of total LV mass [19].
An abnormal CMR was defined by at least one of the
following findings: i) LV ejection fraction (LV-EF) less than
55 %, ii) RV ejection fraction (RV-EF) less than 45 %,
iii) presence of LGE in at least one myocardial segment
(AHA segmentation), and was considered as sign of
cardiac involvement.
Statistical analysis
Continuous variables are expressed as mean ± SD. Skewed
variables are expressed as median and interquartile range
(IQR). Categorical variables are expressed as frequency
with percentage. t-Student test was used for comparison
of normally distributed variables, while Mann-Whitney U
test was used for comparison of non-normally distributed
variables. Non-parametric Kruskal–Wallis test with Bon-
ferroni post-hoc correction was used in case of multiple
comparisons of non-normally distributed variables. The
Chi-square test with Yate’s correction was used to com-
pare non-continuous variables expressed as proportions.
Parametric Pearson or non-parametric Spearman correla-
tions were used as corresponded for correlation analysis.
In order to find independent predictors for abnormal
CMR findings, i.e. LGE presence, a univariable regression
analysis was first performed. Second, the parameters with
significant p-values were introduced into the multivariable
regression analysis. Extremely skewed miRNAs (skewness
statistic < −2 or >2) were Log10 transformed before intro-
duced in the regression analysis. Finally, receiver operating
characteristic curves (ROC) were analyzed to assess
specificity and sensitivity of single plasma miRNAs as
well as their combination using multiple logistic regres-
sion analysis. Statistical analysis was performed using
SPSS software for Windows (version 20, SPSS, Chicago




The study group consisted of 63 male MD patients com-
prising 12 (19 %) patients with DMD and 51 (81 %) with
BMD with a median age of 31 ± 15 yrs (Table 1). DMD pa-
tients were younger compared to BMD ones (18 ± 5 yrs vs.
33 ± 15 yrs, p < 0.0001). The control group comprised 26
healthy male volunteers aged 36 ± 13 yrs (p = 0.09). There
was no patient with a history of coronary artery disease
(CAD) and/or ischemic cardiomyopathy and/or valvular
disease. The respective cardiovascular risk profile is illus-
trated in Table 1. Serum measurements revealed elevated
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hs-Trop values in 30 (48 %) MD patients (p < 0.0001 vs.
controls) whereas NT-proBNP levels were increased in 3
(5 %) MD patients only (p = 0.55 vs. controls).
Major CMR findings
The detailed results of the CMR studies performed in MD
patients and controls are given in Table 2. An impaired
LV systolic function (defined as LV-EF <55 %) was de-
tected in 29 (46 %) MD patients (p < 0.0001 vs. controls)
and a reduced RV systolic function (defined as RV-EF
<45 %) in 10 (16 %) MD patients (p = 0.031 vs. controls).
Presence of LGE indicative of myocardial fibrosis was
detected in 48 (76 %) MD patients (p < 0.0001 vs. controls)
with a median LGE extent of 10 % (IQR 5 %–24 %) of LV
mass and an exclusively non-ischemic pattern (Fig. 1a-b).
There was a strong negative correlation between LGE
extent and LV-EF (Spearman’s rho = -0.753, p < 0.0001).
Altogether, any pathological CMR finding was observed in
49 (78 %) MD patients whereas all subjects in the control
group demonstrated normal CMR findings (p < 0.0001).
No significant differences were seen between DMD and
BMD neither in frequencies of LV and/or RV systolic
impairment (42 % vs. 47 %, p = 1.00 for LV; 25 % vs. 14 %,
p = 0.39 for RV) nor in LGE presence (92 % vs. 73 %,
p = 0.26) or LGE extent. Consequently, there was also
no significant difference in the prevalence of an ab-
normal CMR study between these groups (92 % vs.
75 %, p = 0.27).
miRNA findings in MD patients vs. controls
Plasma miRNA results are shown in Table 3. A significant
up-regulation in MD patients compared to controls was
found for seven out of 17 plasma miRNAs included in the
analysis: miR-206 (91-fold increase, p < 0.0001), miR-20b
(1.5-fold increase, p = 0.048), miR-222 (24-fold, p < 0.0001),
miR-26a (6-fold, p < 0.0001), miR-342 (33-fold, p < 0.0001),
miR-378a-3p (minimum 3000-fold; almost undetectable in
controls, p < 0.0001), miR-378a-5p (48-fold, p < 0.0001).
Additionally, a significant down-regulation was found for
the three miRNAs: miR-221, miR-29a and miR-29c, all
almost undetectable in the plasma of MD patients.
Among MD patients, none of the miRNAs differed
significantly in patients with elevated vs. normal hs-Trop
and NT-proBNP, respectively. Moreover, we did not de-
tect any significant differences in miRNA expression in
MD patients with mild myopathy (clinical degree 0-1 as
defined in our Methods section) compared to those with
advanced/severe myopathy (clinical degree of 2–3)
(Additional file 2: Table S2).
When we assessed the relationship between plasma
miRNAs and age, significant but moderate correlations
were found only for two of them: miR-26a (Spearman’s
rho = +0.312, p = 0.013) and miR-378a-3p (Spearman’s
rho = −0.299, p = 0.017) in the MD group. In contrast,
no significant relationship was found in controls regard-
ing plasma miRNA levels and age.
Assessment of CMR and miRNA findings considering all
CMR results
When MD patients with any abnormal CMR findings
(n = 49; 78 %) were compared to those without (n = 14;
22 %), there was no significant difference regarding age or
MD type (Tables 4 and 5). An elevated hs-Trop plasma
level was more frequently observed in patients with ab-
normal CMR findings compared to those without. How-
ever, only 57 % (n = 28) of those patients with pathological
CMR findings also demonstrated elevation of hs-Trop.
Moreover, there were no significant differences in NT-
proBNP levels between MD patients with abnormal CMR
findings and those without.
As shown in Table 6, there were no significant differ-
ences in any of the measured plasma miRNAs in MD
Table 1 Patient characteristics
MD Controls p value
N = 63 N = 26
Male, n (%) 63 (100) 26 (100) 1.00
Age, years 31 ± 15 36 ± 13 0.09








Hypertension, n (%) 3 (5) 0 (0) 0.55
Diabetes, n (%) 0 (0) 0 (0) 1.00
ACE inhibitor, n (%) 16 (25) 0 (0) 0.005
Beta-blocker, n (%) 14 (22) 0 (0) 0.008
CK, U/L 1226 (653–2424) 120 (99–169) <0.0001
Elevated hs-Trop, n (%) 30 (48) 0 (0) <0.0001
Elevated NT-proBNP, n (%) 3 (5) 0 (0) 0.55
Bold text indicates a significant p-value of <0.05
Table 2 Overview CMR results
MD Controls p value
N = 63 N = 26
LV-EDVi, ml/m2 85 ± 30 86 ± 16 0.80
LV-ESVi, ml/m2 41 ± 21 31 ± 9 0.003
LV-massi, g/m2 60 ± 16 58 ± 10 0.69
LV-EF, % 53 ± 12 64 ± 6 <0.0001
RV-EF, % 53 ± 9 55 ± 8 0.47
LV-EF <55 %, n (%) 29 (46) 0 (0) <0.0001
RV-EF <45 %, n (%) 10 (16) 0 (0) 0.031
LGE presence, n (%) 48 (76) 0 (0) <0.0001
LGE extent, % 7 (1-17) - -
Abnormal CMR, n (%) 49 (78) 0 (0) <0.0001
Bold text indicates a significant p-value of <0.05
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patients with any abnormal CMR finding (comprising
structural and/or functional impairments) compared to
those with completely normal CMR studies.
Assessment of CMR and miRNA findings according to
“functional” CMR results
Fifty-one percent (n = 32) of the MD patients showed a
reduced LV and/or RV systolic function in the CMR
study as measured by the respective EF. In this subgroup
of MD patients with impaired systolic function, both
LGE prevalence and extent were significantly increased
compared to those MD patients with normal biventri-
cular systolic function (n = 31; 49 %) as depicted in
Tables 7 and 8.
However, there were again no significant differences in
any of the measured plasma miRNAs in MD patients
with an impaired systolic function compared to those
without (Table 9). The only significant correlation be-
tween a miRNA and LV-EF was a moderate negative one
for miR-29c (Spearman’s rho = −0.323, p = 0.010).
Assessment of CMR and miRNA findings according to
“structural” CMR results
In the next step, MD patients with presence of structural
abnormalities - defined as presence of LGE (n = 48; 76 %) -
were compared to those without any LGE (n = 15; 24 %).
LGE-positive MD patients showed more frequently a re-
duced LV-EF (28 (58 %) vs. 1 (7 %); p = 0.001) and an
Fig. 1 Examples of cine- and late gadolinium enhancement (LGE)-CMR images of a patient with Duchenne (a) and Becker muscular dystrophy
(b) in short-axis views (upper panels) and 3-chamber views (lower panels). In both, the same non-ischemic, predominantly subepicardial LGE
pattern (arrows) indicating myocardial fibrosis can be seen.
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elevated hs-Trop level (28 (58 %) vs. 2 (13 %); p = 0.003)
compared to LGE-negative ones (Tables 10 and 11).
As illustrated in Table 12, a significant up-regulation
of three miRNAs was observed in LGE-positive MD pa-
tients compared to LGE-negative ones: miR-222 (1.8-
fold, p = 0.035), miR-26a (2.1-fold, p = 0.03) and miR-
378a-5p (2.4-fold, p = 0.026). There was no miRNA that
was significantly down-regulated in the LGE-positive
group compared to the LGE-negative one.
When the miRNA results of LGE-positive and LGE-
negative patients were compared to controls, there were
significant differences when all three groups were con-
sidered (Fig. 2a-c). However, when post hoc analysis for
multiple group comparisons was performed, differences
between MD patients with and without LGE were only
borderline significant for any of the miRNAs – as ex-
pected in case of multiple testing in a small-sized study
group. While in this post hoc comparison circulating
miR-222 and miR-378a-5p levels were significantly
higher both in LGE-positive and LGE-negative patients
compared to controls (p = 0.003 and p < 0.0001 for miR-
222; p = 0.017 and p < 0.0001 for miR-378a-5p), a signifi-
cant difference was noted only between LGE-positive pa-
tients and controls for miR-26a (p < 0.0001) – but not
for LGE-negative ones vs. controls.
Assessment of possible predictors of LGE presence
In order to further characterize the association between
myocardial scarring as detected by LGE-CMR and the
three up-regulated plasma miRNAs, we first performed
univariable logistic regression analyses for a series of po-
tential predictors of LGE occurrence - including miR-
222, miR-26a and miR-378a-5p (Table 13). In this ana-
lysis, a significant association with LGE presence was
found for the following parameters: a) CMR parameters
such as LV-EF, LV-ESVi and LV-mass, b) the serum
marker elevated hs-Trop and c) the miRNAs miR-222
and miR-26a.
In the next step, we performed a multivariable regres-
sion analysis focusing on four variables of most interest
among those being statistically significant variables from
the aforementioned univariable analysis (LV-EF, elevated
hs-Trop, miR-222 and miR-26a). In this multivariable
model, three independent predictors for LGE presence
were found: a) LV-EF (OR 0.47, 95 % CI 0.24-0.89, p =
Table 3 Plasma miRNA results in MD patients vs. controls
miRNA plasma
levelsa (/103)
MD Controls p value
N = 63 N = 26
-206 17.20 (4.29–63.96) 0.19 (0.12–0.64) <0.0001
-144-5p 9.85 (0.00–169.32) 13.16 (6.53–19.63) 0.81
-146b 62.55 (0.00–176.97) 16.64 (6.86–33.02) 0.16
-15b 0.00 (0.00–19.61) 2.46 (0.81–3.93) 0.64
-195 9.01 (0.52–21.73) 13.63 (10.46–16.81) 0.053
-20b 61.74 (21.70–85.10) 35.95 (27.39–51.02) 0.048
-21 30.61 (0.00–110.97) 9.58 (5.86–18.33) 0.48
-221 0.00 (0.00–20.44) 10.61 (7.73–17.12) 0.001
-222 1923.17 (881.56–5111.93) 79.22 (43.34–169.52) <0.0001
-26a 293.34 (121.00–554.69) 49.40 (26.58–63.10) <0.0001
-29a 0.00 (0.00–0.00) 0.07 (0.00–1.11) 0.002
-29c 0.00 (0.00–1.43) 0.56 (0.27–2.72) 0.001
-342 2427.02 (1198.59–4185.82) 73.89 (45.30–171.19) <0.0001
-378a-3p 30 (5.07–268.79) 0.00 (0.00–0.23) <0.0001
-378a-5p 27.57 (8.84–81.04) 0.58 (0.30–1.79) <0.0001
-451 184.13 (73.28–343.07) 144.45 (107.74–169.24) 0.19
-93 26.82 (0.00–66.29) 35.37 (25.60–49.70) 0.24
(a) – Each miRNA plasma level was normalized to miR-16 plasma levels and
thereafter multiplied by 103 in order to increase readability
Bold text indicates a significant p-value of <0.05
Table 4 Patient characteristics and cardiac findings according to CMR results
MD Normal CMR Abnormal CMR p value
N = 63 N = 14 N = 49
Male, n (%) 63 (100) 14 (100) 49 (100) 1.00
Age, years 31 ± 15 25 ± 18 32 ± 14 0.11
BMD, n (%) 51 (81) 13 (93) 38 (78) 0.27
BMI, kg/m2 24 ± 4 23 ± 6 24 ± 4 0.75
Skeletal muscle status 0/1/2/3, n (%) 2 (3)/43 (68)/13 (21)/5 (8) 2 (14)/10 (71)/1 (7)/1 (7) 33 (67)/12 (25)/4 (8)/0 (0) 0.07
ACE inhibitor, n (%) 16 (25) 1 (7) 15 (31) 0.09
Beta-blocker, n (%) 14 (22) 1 (7) 13 (27) 0.16
CK, U/L 1226 (653-2424) 764 (596-2411) 1344 (783-2463) 0.24
Elevated hs-Trop, n (%)a 30 (48) 2 (14) 28 (57) 0.006
Elevated NT-proBNP, n (%)b 3 (5) 0 (0) 3 (6) 1.00
a > 14 pg/mL; b > 450 pg/mL
Bold text indicates a significant p-value of <0.05
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0.021), b) an elevated hs-Trop (OR 2559, 95 % CI 2.97-
22.04*105, p = 0.023) and c) serum miR-222 levels (OR
938, 95 % CI 3.56-24.73*104, p = 0.016).
Plasma miRNAs for the identification of MD patients with
LGE presence
As shown in Fig. 3a-c, the individual receiver operating
characteristics curves (ROC) for the three significantly
up-regulated miRNAs in MD patients with vs. without
LGE revealed areas under the curve (AUC) close to 0.70.
Sensitivities, specificities and overall accuracies for these
miRNAs were as follows: a) miR-26a: 65, 73 and 67 %
(cut-off value of 241.54*10-3), b) miR-222: 62, 80 and
65 % (cut-off value of 1833.18*10-3) and c) miR-378a-
5p: 69, 60 and 67 % (cut-off value of 18.84*10-3).
Furthermore, by combining these three miRNAs (miR-
26a, miR-222 and miR-378a-5p, Fig. 3d) as potential diag-
nostic signature for cardiomyopathy in MD patients, an
improved AUC value of 0.74 was reached with a sensitivity
of 70 %, a specificity of 73 % and an overall accuracy of
70 %. In comparison, ROC analysis for the conventional
serum marker hs-Trop regarding the identification of
LGE-positive MD patients revealed an AUC value of 0.75
with a sensitivity of 63 %, a specificity of 87 % and an over-
all accuracy of 65 % (Fig. 3e). Moreover, there was no sig-
nificant correlation between hs-Trop and each of the
three miRNAs (miR-26a, miR-222 and miR-378a-5p).
Discussion
To the best of our knowledge, this is the first study that
assessed the diagnostic value of circulating miRNAs for
the detection and prediction of functional as well as
structural cardiac impairments (that were assessed by
comprehensive CMR studies) in MD patients. The
present results indicate that some circulating miRNAs
are differently expressed in the plasma of MD patients
compared to healthy volunteers. However, for the first
time we also identified three circulating miRNAs (miR-
26a, miR-222 and miR-378a-5p) that were significantly
up-regulated in MD patients with proof of myocardial
scarring (based on LGE-CMR) compared to those with-
out – independent of the patients’ age and skeletal
muscle status. Interestingly, the association between the
plasma profile of these three miRNAs and the presence
of cardiac disease was only observed in case of structural
changes (proof of myocardial scarring) – but not in case
of exclusive functional abnormalities.
Pathophysiology of cardiac involvement in MD
As outlined previously, the detailed molecular pathome-
chanism leading to cardiac disease in MD patients is still
to be elucidated, although the underlying genetic dys-
trophin defect can be identified easily by appropriate
mutation screening [1]. Based on preclinical studies in
dystrophin deficient animal models, early alterations in
cardiomyocyte metabolism and signal transduction were
suggested [20]. In addition, excessive intracellular calcium
signalling and reactive oxygen species (ROS) generation
with breakdown of the mitochondrial membrane potential
were described and may constitute the link between the
initial sarcolemmal injury due to dystrophin deficiency
and mitochondrial dysfunctions. Of note, De Arcangelis
et al. showed in an animal model that miRNAs are




Normal CMR Abnormal CMR p value
N = 14 N = 49
-206 14.36 (3.07–49.46) 21.76 (4.82–72.71) 0.68
-144-5p 8.94 (0.00–163.41) 9.85 (0.00–171.21) 0.97
-146b 84.15 (40.30–169.65) 38.75 (0.00–177.31) 0.25
-15b 7.44 (0.00–21.87) 0.00 (0.00–18.78) 0.43
-195 9.76 (1.53–19.84) 8.31 (0.57–21.25) 0.86
-20b 49.38 (29.88–79.03) 65.38 (19.43–86.37) 0.66
-21 71.91 (2.89–107.05) 11.48 (0.00–113.69) 0.61






-26a 173.94 (47.45–324.42) 326.81 (126.07–602.29) 0.63
-29a 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.94






-378a-3p 14.15 (0.00–273.74) 39.74 (5.89–290.67) 0.39
-378a-5p 17.32 (2.66–40.41) 39.29 (13.24–101.0) 0.06
-451 104.66 (57.69–312.21) 206.41 (110.79–338.52) 0.27
-93 24.46 (0.38–55.52) 26.95 (0.00–69.92) 0.93
(a) – Each miRNA plasma level was normalized to miR-16 plasma levels and
thereafter multiplied by 103 in order to increase readability
Bold text indicates a significant p-value of <0.05
Table 5 Cardiac findings according to CMR results
MD Normal CMR Abnormal CMR p value
N = 63 N = 14 N = 49
LV-EDVi, ml/m2 85 ± 30 72 ± 19 88 ± 32 0.08
LV-ESVi, ml/m2 41 ± 21 24 ± 7 46 ± 21 <0.0001
LV-mass, g/m2 60 ± 16 52 ± 11 62 ± 17 0.037
LV-EF, % 53 ± 12 67 ± 6 50 ± 11 <0.0001
RV-EF, % 53 ± 9 58 ± 7 52 ± 9 0.023
LV-EF <55 %, n (%) 29 (46) 0 (0) 29 (59) NA
RV-EF <45 %, n (%) 10 (16) 0 (0) 10 (20) NA
LGE presence, n (%) 48 (76) 0 (0) 48 (98) NA
LGE extent, % 7 (1–17) - 10 (4–24) NA
Bold text indicates a significant p-value of <0.05
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involved in the regulation of the dystrophin-glycoprotein
complex components in dystrophic muscles of the mdx
mice. Especially, miR-222 expression was increased in dys-
trophic muscle and led to a decrease of the b1-syntrophin
expression [21]. Taken together, the fragility of the cell
membrane that is caused by deficient sarcolemmal dys-
trophin may predispose not only skeletal muscle cells but
also cardiomyocytes to metabolic dysfunctions, which in
turn may be enhanced by mechanical stress.
In recent years, CMR imaging has gained wide accept-
ance for non-invasive evaluation of ischaemic as well as
non-ischaemic cardiomyopathies since multi-parametric
CMR does not only allow the assessment of functional pa-
rameters (such as systolic function) but also enables a
non-invasive assessment of myocardial scarring based on
LGE-imaging or T1-mapping [22]. Within the last years,
the distribution pattern of myocardial scarring in MD pa-
tients (as well as female MD carriers) was assessed based
on such comprehensive CMR studies and it could be con-
sistently shown that the posterolateral LV wall segments
represent the first and most extensive sites of myocardial
Table 7 Patient characteristics focusing on functional CMR results
MD Normal LV and RV function Impaired LV and/or RV function p value
N = 63 N = 31 N = 32
Male, n (%) 63 (100) 31 (100) 32 (100) 1.00
Age, years 31 ± 15 27 ± 15 34 ± 15 0.11
BMD, n (%) 51 (81) 26 (84) 25 (78) 0.75
BMI, kg/m2 24 ± 4 24 ± 5 24 ± 3 0.72
Skeletal muscle status 0/1/2/3, n (%) 2 (3)/43 (68)/13 (21)/5 (8) 2 (7)/23 (74)/5 (16)/1 (3) 20 (63)/8 (25)/4 (13)/0 (0) 0.20
ACE inhibitor, n (%) 16 (25) 2 (7) 14 (44) 0.001
Beta-blocker, n (%) 14 (22) 4 (13) 10 (31) 0.13
CK, U/L 1226 (653–2424) 1250 (652–3043) 1221 (727–2291) 0.86
Elevated hs-Trop, n (%)a 30 (48) 8 (26) 22 (67) 0.001
Elevated NT-proBNP, n (%)b 3 (5) 0 (0) 3 (9) 0.24
a > 14 pg/mL; b > 450 pg/mL
Bold text indicates a significant p-value of <0.05
Table 8 Cardiac findings focusing on functional CMR results





N = 63 N = 31 N = 32
LV-EDVi, ml/m2 85 ± 30 73 ± 18 96 ± 35 0.003
LV-ESVi, ml/m2 41 ± 21 27 ± 9 54 ± 21 <0.0001
LV-mass, g/m2 60 ± 16 53 ± 11 66 ± 18 0.001
LV-EF, % 53 ± 12 63 ± 6 44 ± 9 NA
RV-EF, % 53 ± 9 58 ± 7 49 ± 9 NA
LV-EF <55 %,
n (%)
29 (46) 0 (0) 29 (91) NA
RV-EF <45 %,
n (%)
10 (16) 0 (0) 10 (31) NA
LGE presence,
n (%)
48 (76) 17 (55) 31 (97) <0.0001
LGE extent, % 7 (1–17) 1 (0–6) 16 (8–32) <0.0001
Abnormal CMR,
n (%)
49 (78) 17 (55) 32 (100) NA
Bold text indicates a significant p-value of <0.05









N = 31 N = 32
-206 31.77 (4.83–79.62) 11.27(3.52–50.27) 0.58
-144-5p 33.14 (0.00–525.08) 0.00 (0.00–98.72) 0.29
-146b 74.79 (0.00–173.85) 29.92 (0.00–177.79) 0.60
-15b 0.00 (0.00–18.15) 0.18 (0.00–21.81) 0.77
-195 9.01 (0.35–18.62) 8.93 (1.90–22.0) 0.66
-20b 53.99 (25.84–83.60) 65.45 (19.35–87.12) 0.66
-21 42.09 (0.00–102.71) 13.65 (0.00–150.01) 0.41






-26a 283.14 (110.62–512.14) 362.31 (121.25–622.72) 0.36
-29a 0.00 (0.00–0.00) 0.00 (0.00–0.05) 0.39






-378a-3p 28.84 (6.04–155.98) 32.92 (1.76–301.61) 0.98
-378a-5p 27.57 (12.50–56.49) 26.02 (7.00–84.56) 0.78
−451 184.13 (100.07–349.44) 171.93 (22.68–307.38) 0.77
−93 26.19 (0.00–70.81) 27.17 (0.00–53.75) 0.81
(a) – Each miRNA plasma level was normalized to miR-16 plasma levels and
thereafter multiplied by 103 in order to increase readability
Bold text indicates a significant p-value of <0.05
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fibrosis in MD patients – as well as their female MD car-
rier relatives [17, 23–25] (Fig. 1). Moreover, we could re-
cently show that a “transmural” pattern of myocardial
fibrosis independently predicts the occurrence of adverse
cardiac events in DMD/BMD patients [23].
Conventional serum markers of cardiac disease in MD
patients
Today, measurement of serum BNP levels is routinely per-
formed in patients presenting with heart failure symptoms
and/or suspected cardiomyopathy (e.g. dilated cardiomy-
opathy) since normal BNP values allow to elegantly rule
out congestive heart failure whereas elevated BNP values
(in patients with normal renal function) point to an
underlying cardiac disease and necessitate further cardiac
examinations such as echocardiography and/or CMR [9].
Interestingly, in the present study (comprising 63 MD pa-
tients), elevated Nt-proBNP levels were measured in three
(5 %) MD patients only – although any abnormal cardiac
findings were detected in 49 (78 %) and a reduced LV-EF
was observed in 29 (46 %) of them by CMR. Hence, meas-
urement of serum BNP is not very sensitive for diagnosing
or ruling out cardiac disease in MD patients. As discussed
previously, one explanation for this observation may be
that serum BNP levels are supposed to reflect rapid
changes of pressure gradients in the atria and ventricles
and one may argue that the underlying pathophysiology in
Table 10 Patient characteristics focusing on structural CMR results
MD LGE-negative LGE-positive p value
N = 63 N = 15 N = 48
Male, n (%) 63 (100) 15 (100) 48 (100) 1.00
Age, years 31 ± 15 25 ± 17 32 ± 14 0.13
BMD, n (%) 51 (81) 14 (93) 37 (77) 0.26
BMI, kg/m2 24 ± 4 23 ± 5 24 ± 4 0.38
Skeletal muscle status 0/1/2/3, n (%) 2 (3)/43 (68)/13 (21)/5 (8) 2 (13)/11 (73)/1 (7)/1 (7) 32 (67)/12 (25)/4 (8)/0 (0) 0.06
ACE inhibitor, n (%) 16 (25) 1 (7) 15 (31) 0.09
Beta-blocker, n (%) 14 (22) 1 (7) 13 (27) 0.16
CK, U/L 1226 (653–2424) 773 (607–2187) 1358 (797-2481) 0.18
Elevated hs-trop, n (%)a 30 (48) 2 (13) 28 (58) 0.003
Elevated NT-proBNP, n (%)b 3 (5) 0 (0) 3 (6) 1.00
a > 14 pg/mL; b > 450 pg/mL
Bold text indicates a significant p-value of <0.05
Table 11 Cardiac findings focusing on structural CMR results
MD LGE-negative LGE-positive p value
N = 63 N = 15 N = 48
LV-EDVi, ml/m2 85 ± 30 72 ± 18 89 ± 32 0.06
LV-ESVi, ml/m2 41 ± 21 25 ± 7 46 ± 22 <0.0001
LV-mass, g/m2 60 ± 16 51 ± 11 62 ± 17 0.018
LV-EF, % 53 ± 12 66 ± 6 50 ± 11 <0.0001
RV-EF, % 53 ± 9 56 ± 10 52 ± 9 0.15
LV-EF <55 %, n (%) 29 (46) 1 (7) 28 (58) 0.001
RV-EF <45 %, n (%) 10 (16) 1 (7) 9 (19) 0.43
LGE extent, % 7 (1–17) - 10 (5–24) NA
Abnormal CMR, n (%) 49 (78) 1 (7) 48 (100) NA
Bold text indicates a significant p-value of <0.05




LGE-negative LGE-positive p value
N = 15 N = 48
-206 13.18 (3.69–43.72) 22.85 (4.56–74.83) 0.54
-144-5p 15.70 (0.00–159.39) 4.93 (0.00–191.57) 0.95
-146b 81.86 (32.74–162.66) 44.23 (0.00–177.79) 0.32
-15b 7.42 (0.00–21.10) 0.00 (0.00–19.01) 0.41
-195 10.50 (2.70–17.48) 8.19 (0.54–21.93) 0.75
-20b 46.56 (31.69–74.64) 65.45 (19.35–86.58) 0.58
-21 67.48 (5.74–106.23) 11.82 (0.00–115.78) 0.65






-26a 165.39 (36.75–291.31) 345.01 (139.78–616.20) 0.030
-29a 0.00 (0.00–.09) 0.00 (0.00–0.00) 0.61






-378a-3p 13.18 (0.00–155.98) 40.31 (8.05–301.61) 0.26
-378a-5p 16.99 (1.04–36.13) 41.23 (14.62–102.03) 0.026
-451 106.88 (64.56–273.40) 207.05 (100.16–340.80) 0.29
-93 23.85 (0.77–52.24) 27.17 (0.00–70.37) 0.89
(a) – Each miRNA plasma level was normalized to miR-16 plasma levels and
thereafter multiplied by 103 in order to increase readability
Bold text indicates a significant p-value of <0.05
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MD patients is mainly driven by continuous myocardial
cell death (due to dystrophin absence or fragility) resulting
secondarily in a continuous and adapted ventricular en-
largement with progressive decrease of systolic function,
however, without quick changes in atrial/ventricular filling
pressures [10, 26, 27].
Furthermore, measurement of serum troponin is rou-
tinely performed nowadays not only in patients with acute
chest pain syndromes but also in those with (suspected)
non-ischemic cardiomyopathy for further detailed classifi-
cation and risk stratification of such patients [28, 29]. In
particular, an elevated level of high-sensitive troponin is
believed to be an accurate serum marker of myocardial
cell death in various acute settings. In the present study,
an elevated serum level of hs-Trop was detected in 30
(48 %) MD patients only - although (as aforementioned)
any abnormal cardiac findings were detected in 49 (78 %)
and proof of myocardial scarring/damage in 48 (76 %) of
the study MD patients by CMR. Hence, measurement of
serum hs-Trop in MD patients does not allow to de-
tect all of those MD patients who have at least some
structural cardiac abnormalities - as can be depicted by
LGE-CMR. Moreover, even hs-Trop is not 100 % specific
Fig. 2 Expression of circulating miRNA-26a (a), miRNA-222 (b) and
miR-378a-5p (c) in plasma of LGEnegative (N = 15) and LGE-positive
(N = 48) muscular dystrophy patients as well as controls (N = 26).
Each miRNA plasma level was normalized to miR-16 plasma levels
and thereafter multiplied by 103 in order to increase readability. LGE:
late gadolinium enhancement
Table 13 Univariable analysis regarding predictors for LGE
presence
Variable (N = 63) OR (95 % CI) p value
Age, years 1.03 (0.99–1.08) 0.13
BMD, n (%) 4.16 (0.49–35.28) 0.19
Skeletal muscle status 0/1/2/3, n (%) 2.83 (0.84–9.50) 0.09
Log10 CK, U/L 1.69 (0.39–7.36) 0.48
LV-EDVi, ml/m2 1.02 (0.99–1.05) 0.06
LV-ESVi, ml/m2 1.11 (1.04–1.19) 0.003
LV-mass, g/m2 1.06 (1.01–1.11) 0.024
LV-EF, % 0.81 (0.71–0.91) 0.001
Elevated hs-Trop, n (%)a 9.1 (1.85–44.87) 0.007
miR-222 (/103)c,d 2.51 (1.01–6.21) 0.047
miR-378a-5p (/103)c,d 1.00 (0.99–1.01) 0.86
miR-26a (/103)c 12.86 (1.07–154.34) 0.044
a > 14 pg/mL
(b) – Each miRNA plasma level was normalized to miR-16 plasma levels and
thereafter multiplied by 103 in order to increase readability
(c) - Log10 transformed before introduced in the regression analysis
Bold text indicates a significant p-value of <0.05
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for cardiac disease and may also originate from cell death
of skeletal muscle myocytes – particularly in patients with
neuromuscular disorders and advanced skeletal myopathy.
Taken together, a normal hs-Trop level in a MD patient
does not always rule out cardiac disease and in contrast,
an elevated hs-Trop level does not necessarily indicate the
presence of cardiac abnormalities. Therefore, novel (more
sensitive as well as more specific) markers are wanted for
early and accurate diagnosis of cardiac involvement in
MD patients.
Circulating miRNAs as novel biomarkers of cardiac
disease in MD patients
Recent advances in molecular diagnostics have shown that
circulating miRNAs can be used as diagnostic as well as
prognostic biomarkers for different cardiovascular dis-
eases [14, 15]. Therefore, we tested the hypothesis that the
pattern of plasma miRNA expression would also allow the
diagnosis and prediction of cardiac disease in MD pa-
tients. In a first step, we searched for those miRNAs that
were known to be associated with either cardiovascular
diseases and/or DMD/BMD based on the available litera-
ture data [30–38]. Compared to our control group, we
identified seven significantly up-regulated plasma miRNAs
(miR-206, miR-20b, miR-222, miR-26a, miR-342, miR-
378a-3p, miR-378a-5p) and three down-regulated miRNAs
(miR-221, miR-29a and miR-29c) in MD patients (Table 3).
Since we did not detect any significant differences in
miRNA expression in MD patients with mild myop-
athy (clinical degree 0-1 as defined in our Methods
section) compared to those with advanced/severe my-
opathy (clinical degree of 2-3), the aforementioned
seven up-regulated and three down-regulated miRNAs
do not seem to reflect the skeletal myopathy status of our
MD patients.
In the next step, we looked at those MD patients who
had any abnormal CMR findings compared to those with
completely normal CMR results. Interestingly, there were
no significant differences in any of the measured plasma
miRNAs (Table 6). Then, we focused first on “functional”
Fig. 3 Receiver operating characteristic (ROC) analysis of individual (a-c) and combined (d) plasma miRNA-26a, miRNA-222 and miR-378a-5p to
discriminate LGE-negative (N = 15) from LGE-positive (N = 48) muscular dystrophy patients. Each miRNA plasma level was normalized to miR-16
plasma levels and thereafter multiplied by 103 in order to increase readability. e ROC analysis for the conventional serum marker high-sensitive
troponin (hs-Trop). LGE, late gadolinium enhancement. AUC, area under the curve
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cardiac parameters and thereafter on “structural” ones.
Again, we did not detect significant differences in any of
the measured plasma miRNAs in MD patients when
those with an impaired systolic function were compared to
those without (Table 9). However, patients with proof of
myocardial scarring (LGE-positive) compared to those
without (LGE-negative) showed a significant up-regulation
of three miRNAs (miR-222, miR-26a and miR-378a-5p,
Table 12). Importantly, there was no significant difference
in the degree of skeletal myopathy or serum CK in LGE-
positive MD patients compared to LGE-negative ones.
Hence, the elevation of these three miRNAs in LGE-
positive MD patients was not (only) caused by skeletal
myopathy, but rather reflected cardiac disease.
Additional univariable analyses revealed a significant and
substantial association between the expression level of two
miRNAs (miR-222 and miR-26a) and the presence of
myocardial scarring. Furthermore, multivariable regression
analysis revealed three independent predictors for the pres-
ence of LGE – one being a miRNA (miR-222) in addition
to a clinical (LV-EF) and a laboratory marker (elevated hs-
Trop). Taken together, an up-regulation of three circulating
miRNAs miR-222, miR-26a and miR-378a-5p is a useful
signal for the presence of cardiac (structural) disease in MD
patients – with miR-222 being the strongest and most
important biomarker.
Diagnostic value of plasma miRNAs compared to hs-Trop
In the present study, serum hs-Trop was a significant pre-
dictor of myocardial scarring – similar to miR-222. For
further evaluation of the diagnostic value of the detected
miRNAs in comparison to hs-Trop, we performed ROC
analyses regarding the identification of LGE-positive MD
patients. Area under the curve (AUC) values for the indi-
vidual miRNAs (miR-222, miR-26a and miR-378a-5p)
were close to 0.70. However, combining these three miR-
NAs resulted in an improved AUC value of 0.74 – com-
pared to 0.75 in case of hs-Trop. However, the respective
sensitivity, specificity and overall accuracy was 70, 73 and
70 % for the combination of these three miRNAs com-
pared to 63, 87 and 65 % in case of hs-Trop. Hence, a
combined approach based on the measurement of the
three plasma miRNAs miR-222, miR-26a and miR-378a-
5p seems to be at least as sensitive and accurate for the
non-invasive diagnosis of cardiac disease in MD patients
as the conventional hs-Trop measurement. Moreover, hs-
Trop elevations may also have extra-cardiac causes (e.g.
renal failure or myositis) – which so far were not de-
scribed for the three identified circulating miRNAs. In
future studies, the potential superior diagnostic as well as
prognostic value of a miRNA-based approach for diagno-
sis of cardiomyopathy compared to established measure-
ments (e.g. hs-Trop) needs to be evaluated in larger study
groups.
Comparison of present miRNA results to previous
literature data
In the last years, several studies have been published ad-
dressing both pre-clinical animal models and humans as
well as different biological materials such as skeletal muscle,
heart muscle and serum/plasma. Previously published stud-
ies that (amongst others) addressed the three miRNAs
miR-222, miR-26a and miR-378a-5p are summarized in the
Additional file 3: Table S3. For example, miRNA analyses in
the skeletal muscle of mdx mice and DMD patients re-
vealed an up-regulation of miRNAs associated with muscle
regeneration (e.g. miR-206) and inflammation (e.g. miR-
222) and a down-regulation of miRNAs associated with
muscle degeneration (e.g. miR-29c) [31].
Recently, Jeanson-Leh et al. analysed circulating miRNA
profiles in golden retriever muscular dystrophy dogs and
also evaluated the association of miRNA to cardiac disease
[33]. Importantly, evaluation of cardiac disease was based
only on functional analyses using echocardiography. Al-
though a dysregulation of numerous miRNAs (such as
miR-1, miR-95, miR-133, miR-208a/b, miR-206, miR-378
and miR-499) was detected in the serum of these dogs,
there was no correlation between any miRNAs and car-
diac functional parameters in this model. In agreement
with this study, we also detected a dysregulation of some
circulating miRNAs (e.g. miR-206 and miR-378) in the
plasma of MD patients. Notably, we elucidated only a sig-
nificant association between miRNA and cardiac invol-
vement in MD patients when we looked specifically at
structural – but not functional - abnormalities using
myocardial scarring based on LGE-CMR. Obviously,
miRNA profiling may improve the understanding of the
pathophysiology of a certain disease if in depth phenotypic
characterisation is considered.
Limitations
Since the number of study patients was limited, replication
of our data in an independent cohort is mandatory to dem-
onstrate clinical utility. Moreover, in the present study we
focused on selected miRNAs with evidence from previous
studies. Thus, it cannot be excluded that additional miR-
NAs might even improve the predictive ability of the iden-
tified miRNA signature e.g. by comprehensive microarray
profiling for miRNA expression. Finally, this was a pilot
study and the results need verification in a larger cohort,
with a multi-center approach and with consideration of
clinical outcomes to define the respective role of miRNAs.
Conclusions
Up-regulation of circulating miRNAs miR-222, miR-26a
and miR-378a-5p indicates the presence of myocardial
scars in MD patients. Plasma miR-222 appears to be a
promising novel biomarker reflecting structural – but not
functional – cardiac alterations in MD patients.
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